128 related articles for article (PubMed ID: 23200896)
1. Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis.
Kaku S; Uemura T; Saitoh M; Suzuki K; Iwatsuki Y; Funatsu T; Kawasaki T
Eur J Pharmacol; 2013 Jan; 699(1-3):40-7. PubMed ID: 23200896
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Iwatsuki Y; Sato T; Moritani Y; Shigenaga T; Suzuki M; Kawasaki T; Funatsu T; Kaku S
Eur J Pharmacol; 2011 Dec; 673(1-3):49-55. PubMed ID: 22040919
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Konishi N; Hiroe K; Kawamura M
Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
[TBL] [Abstract][Full Text] [Related]
4. Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models.
Funatsu T; Yamashita A; Kaku S; Iwatsuki Y; Asada Y
Thromb Haemost; 2012 Nov; 108(5):896-902. PubMed ID: 23052641
[TBL] [Abstract][Full Text] [Related]
5. Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa.
Kaku S; Suzuki M; Saitoh M; Funatsu T; Uemura T; Suzuki K; Iwatsuki Y; Kawasaki T
Thromb Res; 2013 May; 131(5):450-6. PubMed ID: 23591155
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
[TBL] [Abstract][Full Text] [Related]
7. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Pehrsson S; Johansson K; Kjaer M; Elg M
Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
[TBL] [Abstract][Full Text] [Related]
9. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
10. SR123781A, a synthetic heparin mimetic.
Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
12. Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban.
Apostolakis S; Lip GY
Expert Opin Investig Drugs; 2012 Jul; 21(7):1057-64. PubMed ID: 22616561
[TBL] [Abstract][Full Text] [Related]
13. Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects.
Cipriani TR; Gracher AH; de Souza LM; Fonseca RJ; Belmiro CL; Gorin PA; Sassaki GL; Iacomini M
Thromb Haemost; 2009 May; 101(5):860-6. PubMed ID: 19404539
[TBL] [Abstract][Full Text] [Related]
14. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
15. Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.
Hirayama F; Koshio H; Ishihara T; Hachiya S; Sugasawa K; Koga Y; Seki N; Shiraki R; Shigenaga T; Iwatsuki Y; Moritani Y; Mori K; Kadokura T; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
J Med Chem; 2011 Dec; 54(23):8051-65. PubMed ID: 21995444
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
[TBL] [Abstract][Full Text] [Related]
17. A novel antithrombin-heparin covalent complex: antithrombotic and bleeding studies in rabbits.
Chan AK; Berry L; Klement P; Julian J; Mitchell L; Weitz J; Hirsh J; Andrew M
Blood Coagul Fibrinolysis; 1998 Oct; 9(7):587-95. PubMed ID: 9863706
[TBL] [Abstract][Full Text] [Related]
18. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
Farias WR; Nazareth RA; Mourão PA
Thromb Haemost; 2001 Dec; 86(6):1540-6. PubMed ID: 11776325
[TBL] [Abstract][Full Text] [Related]
19. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
Morishima Y; Kamisato C; Honda Y
Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
[TBL] [Abstract][Full Text] [Related]
20. The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
Cho JH; Yun CH; Seo HS; Koga T; Dan T; Koo BA; Kim HY
Thromb Haemost; 2001 Dec; 86(6):1512-20. PubMed ID: 11776321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
